SMN1 and proximal spinal muscular atrophy: Also, the Food and Drug Administration (FDA) has approved an antisense oligonucleotide directed against mutant survival motor neuron gene 1 (SMN1) for treatment of spinal muscular atrophy (Bezard et al., 2013), characterized by alteration of lower motor neurons.